New combo aims to deepen remission in Tough-to-Treat myeloma
NCT ID NCT05801939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a drug called cevostamab after standard CAR T cell therapy can help people with relapsed or refractory multiple myeloma achieve a deeper remission. About 30 adults who have already received CAR T cells will get cevostamab infusions every 3 weeks for up to 8 cycles. The main goal is to see if more patients become cancer-free at the 12-month mark.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States